BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 17532097)

  • 21. Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function.
    Kapusta DR; Burmeister MA; Calo' G; Guerrini R; Gottlieb HB; Kenigs VA
    J Pharmacol Exp Ther; 2005 Aug; 314(2):643-51. PubMed ID: 15855356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.
    Ibba M; Kitayama M; McDonald J; Calo G; Guerrini R; Farkas J; Toth G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):553-61. PubMed ID: 18807245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.
    Rizzi A; Malfacini D; Cerlesi MC; Ruzza C; Marzola E; Bird MF; Rowbotham DJ; Salvadori S; Guerrini R; Lambert DG; Calo G
    Br J Pharmacol; 2014 Sep; 171(17):4138-53. PubMed ID: 24903280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice.
    Nazzaro C; Rizzi A; Salvadori S; Guerrini R; Regoli D; Zeilhofer HU; Calo G
    Peptides; 2007 Mar; 28(3):663-9. PubMed ID: 17161885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
    Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
    Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.
    Gavioli EC; Vaughan CW; Marzola G; Guerrini R; Mitchell VA; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo' G
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):547-53. PubMed ID: 15197534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.
    Molinari S; Camarda V; Rizzi A; Marzola G; Salvadori S; Marzola E; Molinari P; McDonald J; Ko MC; Lambert DG; Calo' G; Guerrini R
    Br J Pharmacol; 2013 Jan; 168(1):151-62. PubMed ID: 22827708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies.
    Rizzi D; Rizzi A; Bigoni R; Camarda V; Marzola G; Guerrini R; De Risi C; Regoli D; Calo' G
    J Pharmacol Exp Ther; 2002 Jan; 300(1):57-63. PubMed ID: 11752097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
    Rizzi A; Sukhtankar DD; Ding H; Hayashida K; Ruzza C; Guerrini R; Calò G; Ko MC
    Br J Pharmacol; 2015 Jul; 172(14):3661-70. PubMed ID: 25828800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor.
    Chang M; Peng YL; Dong SL; Han RW; Li W; Yang DJ; Chen Q; Wang R
    Regul Pept; 2005 Sep; 130(3):116-22. PubMed ID: 15935490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
    Marti M; Mela F; Veronesi C; Guerrini R; Salvadori S; Federici M; Mercuri NB; Rizzi A; Franchi G; Beani L; Bianchi C; Morari M
    J Neurosci; 2004 Jul; 24(30):6659-66. PubMed ID: 15282268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.
    D'Agostino B; Marrocco G; De Nardo M; Calò G; Guerrini R; Gallelli L; Advenier C; Rossi F
    Br J Pharmacol; 2005 Mar; 144(6):813-20. PubMed ID: 15685213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats.
    Kapusta DR; Chang JK; Kenigs VA
    J Pharmacol Exp Ther; 1999 Apr; 289(1):173-80. PubMed ID: 10087001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies.
    Rizzi A; Molinari S; Marti M; Marzola G; Calo' G
    Neuropharmacology; 2011 Mar; 60(4):572-9. PubMed ID: 21184763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation.
    Basso M; Risse PA; Naline E; Calo G; Guerrini R; Regoli D; Advenier C
    Peptides; 2005 Aug; 26(8):1492-6. PubMed ID: 16042989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ.
    Guerrini R; Marzola E; Trapella C; Pela' M; Molinari S; Cerlesi MC; Malfacini D; Rizzi A; Salvadori S; Calo' G
    Bioorg Med Chem; 2014 Jul; 22(14):3703-12. PubMed ID: 24878361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
    Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
    Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.
    Rizzi A; Nazzaro C; Marzola GG; Zucchini S; Trapella C; Guerrini R; Zeilhofer HU; Regoli D; Calo' G
    Pain; 2006 Sep; 124(1-2):100-8. PubMed ID: 16697109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
    Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
    Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.